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Abstract: Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung 
function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular signifi-
cance. Approximately 40% of the AECOPD patients who require hospitalization will die in the subsequent year. Since many AECOPD 
require hospitalization, they account for most of the expense of caring for COPD patients. Treatment with long-acting bronchodila-
tors and combination inhaled corticosteroid/long-acting   bronchodilator inhalers reduces but does not eliminate AECOPD. Roflumilast, 
a selective phosphodiesterase 4 (PDE4) inhibitor, is an anti-inflammatory medication that improves lung function in patients with 
COPD. In patients with more severe airway obstruction, clinical features of chronic bronchitis, and a history of AECOPD, roflumi-
last reduces the frequency of AECOPD when given in combination with short-acting bronchodilators, long-acting bronchodilators, 
or inhaled corticosteroids. It is generally well tolerated but the most common adverse effects include diarrhea, nausea, weight loss, and 
headaches. In clinical trials, patients treated with roflumilast experienced weight loss that averaged just over 2 kg but was primarily 
due to the loss of fat tissue. Weight loss was least in underweight patients and obese patients experienced the greatest weight loss. An 
unexpected benefit of treatment with roflumilast was that fasting blood glucose and hemoglobin A1c levels improved in patients with 
comorbid type 2 diabetes mellitus. Roflumilast, the first selective PDE4 inhibitor to be marketed, is a promising drug for the manage-
ment of COPD patients with more severe disease.
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Introduction
Chronic  obstructive  pulmonary  disease  (COPD)  is 
the comprehensive term used to describe the   variable 
amounts  of  emphysema,  chronic  bronchitis,  and 
small airway disease that develop as a consequence 
of exposure to cigarette smoke and other forms of 
air pollution.1 In the developing world, smoke from 
the burning of biomass for cooking and heating is 
the  other  most  common  cause  of  COPD.1,2  COPD 
is   characterized by a different pattern of pulmonary 
inflammation  than  asthma. The  primary  inflamma-
tory cells in the airways of asthma patients are CD4+ 
T lymphocytes and eosinophils whereas in COPD, 
the  predominant  inflammatory  cells  are  CD68+ 
  macrophages, CD8+ T lymphocytes, and neutrophils, 
especially during exacerbations.4 These inflammatory 
changes  contribute  to  airway    swelling,  luminal 
narrowing and a reduction in airflow.5 Airway mucus 
gland hyperplasia results in mucus hypersecretion that 
contributes to cough and sputum production and to 
the  further  impairment  of  airflow.  The  associated 
parenchymal destruction, called emphysema, reduces 
elastic recoil further diminishing airflow.
The severity of inflammation increases with more 
severe  airway  obstruction.3,5  In  COPD  patients, 
elevated  blood  leukocyte  counts  are  common 
  suggesting  that  inflammation  extends  systemically 
from the lungs.6 Fibrinogen and C reactive protein 
concentrations may be elevated in the circulation of 
COPD patients.6 Concentrations of proinflammatory 
cytokines including tumor necrosis factor-α (TNF-α), 
leukotriene B4 (LT B4), interleukin-1β (IL-1β), IL-6, 
and  IL-8  are  also  increased  in  COPD  patients.6,7 
Bronchial epithelial cells, CD8+ T lymphocytes, and 
CD68+ macrophages produce IL-32, contributing to 
increases in the levels of TNF-α, IL-8 and CXCL 2.6 
Blood levels of IL-32 are inversely related to FEV1, 
and increase with the severity of airflow obstruction 
in COPD patients.7
Despite therapeutic advances that have improved 
survival,  symptoms,  and  quality  of  life,  COPD 
remains  a  major  cause  of  disability  and  death. 
Increased smoking rates in the developing world will 
make COPD the 3rd most common cause of death 
worldwide by the year 2020.1 The longitudinal 3 year 
‘Evaluation  of  COPD  Longitudinally  to  Identify 
Predictive  Surrogate  End-points’  (ECLIPSE)  study 
found  that  patients  with  COPD  experience  more 
shortness of breath and have poorer quality of life 
scores than smokers with normal lung function.8 They 
are also more susceptible to a variety of comorbid 
illnesses including heart and cardiovascular disease, 
anemia,  osteoporosis,  diabetes,  muscle  mass  loss, 
and depression than either smokers without airway 
obstruction  or  normal  subjects.9  One  hypothesis 
proposes that inflammation extends systemically from 
the lungs contributing to the comorbidities but which, 
if any, of the inflammatory markers are predictive of 
the relationship between these illnesses and COPD is 
unclear.10
Acute Exacerbations of COPD
Acute exacerbation of COPD (AECOPD) is the term 
used to describe a flare-up of the condition. They are 
important clinical events and have prognostic signifi-
cance.1 They interfere with normal activity and both 
moderate  and  severe  AECOPD  require  treatment 
with  antibiotics  and/or  systemic  corticosteroids.10 
Complete  recovery  from  an  AECOPD  may  take 
weeks to months. Exacerbations are associated with 
worse quality of life scores and with a more rapid 
decline in lung function.11,12 More severe AECOPD 
result  in  hospitalization  accounting  for  the  major-
ity  of  health  care  costs  associated  with  COPD.  In 
  Canada, AECOPD  account  for  more  hospital  days 
than myocardial infarction, congestive heart failure, 
or pneumonia.13 In 2008, patients hospitalized with an 
AECOPD in Canada spent an average of 10 days in 
hospital at an average cost of approximately $10000 
per hospitalization.13 In-hospital mortality rates range 
from 2.5% to 14% and average 7% in patients with 
an  AECOPD.14  The  heightened  risk  of  mortality 
  associated with AECOPD extends beyond the period 
of    hospitalization.  As  many  as  40%  of  AECOPD 
patients requiring hospitalization will die in the sub-
sequent 12 months.15 A more recent Canadian study 
found  that  patients  discharged  after  an  AECOPD 
have a poor prognosis with approximately 30% dying 
in the subsequent 12 months.16
The ECLIPSE Study
The  results  of  a  large,  3  year  longitudinal  study 
of  COPD  patients  and  two  control  groups;  nor-
mal  nonsmokers  and  smokers  without  COPD,  are 
being  reported  in  a  series  of  publications.8  In  the 
ECLIPSE  study,  patients  with  more  severe  COPD Roflumilast in COPD
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experience  more  frequent  AECOPD.17  However, 
there are wide ranges in AECOPD frequency across 
the different GOLD stages. Some patients with moder-
ate COPD, GOLD stage II disease, experienced fre-
quent AECOPD and some with very severe COPD, 
ie, GOLD stage IV with a FEV1 less than 30% of the 
predicted  value,  did  not  experience  any AECOPD 
during the three year prospective study. A patient’s 
AECOPD  history  predicts  what  happens  to  them 
subsequently.  During  the  ECLIPSE  study,  patients 
with a history of frequent, ie, two or more per year, 
AECOPD were more likely to continue to experience 
frequent AECOPD and those without a history of fre-
quent AECOPD were unlikely to experience frequent 
AECOPD.17 Patients with more frequent AECOPD 
had poorer quality of life scores.17
Chronic Bronchitis
Chronic bronchitis is defined clinically as an almost 
daily  productive  cough  for  a  minimum  of  three 
months  for  a  minimum  of  two  consecutive  years. 
Patients with chronic bronchitis are at greater risk for 
poor outcomes than other COPD patients with similar 
degrees of airway obstruction.18 Airway inflamma-
tion is greater in patients with the chronic bronchitis 
clinical phenotype.19 There is also evidence that they 
experience a more rapid decline in lung function than 
other COPD patients.20,21 Although not reported in the 
ECLIPSE study, other investigators have reported that 
patients with chronic bronchitis experience exacerba-
tions more frequently and a have higher death rate.18
AECOPD
Potential causes of AECOPD include air   pollution, 
allergen  exposure,  heart  failure,  and  pulmonary 
emboli, but the majority are triggered by   bacterial 
or  viral  infections.10  Many  COPD  patients  are 
chronically  colonized  with  bacteria,  primarily 
Hemophilus  influenzae,  Moraxella  catarrhalis, 
and  Streptococcus  pneumoniae  and  these  are  also 
the  most  commonly  isolated  bacterial  pathogens 
  during  AECOPD.22  Exacerbations  are  associated 
with an increase in airway inflammation.21 Sethi and 
  colleagues follow a large cohort of chronic bronchitis 
subjects who provide them with serial sputum and 
serum  samples.22  Patients  with  chronic  bronchitis 
develop specific immunity to the bacterial strains in 
their sputum.23 Exacerbations occur more commonly 
when  patients  acquire  a  new  bacterial  strain  and 
recovery from the AECOPD is associated with the 
development  of  specific  immunity  to  the  newly 
acquired bacterial strain.22,23
Treatment of AECOPD
Antibiotics  have  been  used  to  treat AECOPD  for 
over 50 years despite numerous studies in the 1950s, 
1960s, and 1970s failing to confirm their   benefits.24 
Anthonisen and colleagues recognized that β error, 
ie, earlier studies did not recruit enough subjects to 
  consistently  demonstrate  their  effectiveness,  was 
responsible and that a properly powered study might 
confirm the impression of most clinicians that antibi-
otics are advantageous in AECOPD. They designed 
a study that randomized patients with AECOPD to 
treatment with antibiotics, cotrimoxasole,   doxycycline, 
or ampicillin, or to placebo.25 Those treated with anti-
biotics had a 68% treatment success rate compared 
to 55%, (P , 0.05), in   placebo-treated patients. The 
treatment success rate was 63% in patients with all 
three features of an infectious AECOPD,   dyspnea, 
increased  sputum  volume,  and  increased  sputum 
purulence,  who  received  antibiotics  compared  to 
only  43%  in  similar  patients  treated  with  placebo 
(P , 0.05).
Systemic  corticosteroids  are  also  beneficial  in 
AECOPD. Aaron and colleagues randomized patients 
discharged from the emergency room to receive either 
prednisone 40 mg daily for 10 days or placebo. The 
relapse  rate  was  27%  in  the  corticosteroid-treated 
patients compared to 43% in the placebo-treated group 
(P , 0.05).26 Other studies have also shown that treat-
ing AECOPD with antibiotics and corticosteroids is 
beneficial.
Prevention of AECOPD
The inflammatory changes associated with AECOPD 
contribute to symptoms and require time to recover. 
Corticosteroids  are  anti-inflammatory  but  have 
greater  activity  against  CD4+  T  lymphocytes  and 
  eosinophils, than on the predominant inflammatory 
cells  in  COPD;  CD8+  T  lymphocytes,  CD68+ 
macrophages  and  neutrophils.3,7  Other  strategies, 
including the introduction of novel medications with 
greater   activity against the predominant inflammatory 
cells in COPD, will likely further reduce both the 
frequency and severity of AECOPD.Field
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Obvious strategies include the prevention of COPD 
by smoking cessation and controlling air pollution, 
and the development of more effective medications 
to improve pulmonary function, reduce the rate of 
  pulmonary function decline, and to prevent AECOPD. 
Moderate AECOPD are usually defined as increases 
in, or the new onset of cough, increased sputum pro-
duction,  increased  sputum  purulence,  wheezing  or 
dyspnea, or various combinations of these symptoms 
requiring  treatment  with  antibiotics,  oral  corticos-
teroids, or both.27,28 Severe AECOPD are defined as 
those requiring hospitalization or resulting in death.28 
Several treatment options reduce the number or fre-
quency of AECOPD and the number of AECOPD 
requiring hospitalization. Recent studies have found 
that treatment with tiotropium, combination inhaled 
corticosteroid (IHCS)/long-acting β2 agonist (LABA) 
inhalers, and treatment with tiotropium and combi-
nation IHCS/LABA inhalers reduce the number of 
AECOPD; especially in those with more advanced 
disease.28–33
Uncertainty  persists  about  the  role  of  IHCS 
in  COPD.  Treatment  with  IHCS  is  not  beneficial 
in patients with mild COPD.34,35 However, studies in 
patients with more severe COPD suggested that IHCS 
were  beneficial.36,37  A  meta-analysis  of  the  IHCS 
treatment  trials  concluded  that  IHCS  reduced  all 
cause mortality by approximately 25%.38 The study 
design and analysis of these trials have been criti-
cized and their validity contested.39 In some studies, 
the majority of patients were receiving IHCS prior to 
entering the trials. The apparent benefits of IHCS on 
the AECOPD rate increased with the proportion of 
patients taking IHCS prior to randomization.39 Many 
of the patients previously treated with IHCS were 
randomized to the placebo arm and so their outcomes 
actually represent the effects of IHCS withdrawal, 
shown  previously  to  adversely  affect  outcomes  in 
severe COPD, and contributed to an overestimate of 
the apparent benefits of IHCS therapy.39,40 Another 
concern with these studies is that patients who with-
drew prematurely were not always followed to the 
end of the trial potentially biasing the intent-to-treat 
analysis.39 Some studies did not employ a weighted 
Poisson regression model and underestimated vari-
ability.39 Consequently, the 95% confidence intervals 
were under estimated, falsely attributing statistical 
significance to the results.40
A  retrospective  patient  database  analysis 
  demonstrated that hospitalized AECOPD patients who 
received an IHCS prescription within three months of 
discharge had lower mortality rates and lower rates of 
rehospitalization.42 Patients who were rehospitalized 
or  died  prior  to  filling  an  IHCS  prescription  were 
included in the non-IHCS group biasing the results. 
By including those with a poorer outcome in the non-
IHCS group, the apparent benefits of IHCS therapy 
were  exaggerated.43  This  source  of  error  is  called 
immortal time bias.44 In a subsequent study of newly 
diagnosed COPD patients, bronchodilator users were 
compared  to  IHCS  users  to  avoid  immortal  time 
bias influencing the results.45 In this study, mortality 
was not less in the IHCS treated-patients.44 Another 
  concern is that treatment with IHCS may increase the 
risks of pneumonia and possibly also of tuberculosis 
in  COPD  patients.46,47  Current  COPD  guidelines 
  recommend  against  the  use  of  IHCS  monotherapy 
because of doubts about their efficacy and their poten-
tially serious side effects.4
Despite  IHCS  monotherapy  not  being  recom-
mended,  IHCS  may  be  beneficial  when  combined 
with LABA, especially in patients with more severe 
COPD; primarily GOLD stage III and GOLD stage IV 
disease and in patients with frequent AECOPD. Prop-
erly powered, randomized, placebo-controlled studies 
of combination IHCS/LABA inhalers using an intent-
to-treat analysis, have reported clinically important 
benefits including reductions in moderate and severe 
AECOPD (Tables 1 and 2).29–31 Controversy persists 
about the benefits of combining IHCS with LABA.39 
An  alternative  interpretation  of  the  TORCH  study 
data, using a 2 × 2 factorial analysis to analyze the 
effects on mortality, concluded that the benefits from 
combination therapy can be attributed to salmeterol 
xinafoate rather than to fluticasone propionate.39
In  the  randomized,  placebo-controlled  UPLIFT 
trial, daily tiotropium for 4 years was added to the reg-
ular treatment regimen of COPD patients.32 Improve-
ments in pulmonary function, respiratory symptoms, 
and quality of life were reported in the tiotropium-
treated patients. The rate of lung function decline was 
the primary objective so final outcomes were assessed 
one month after the end of the trial to allow for an ade-
quate washout period.32 Mortality was reduced at the 
end of the trial in the tiotropium-treated patients but 
the difference was no longer evident one month later.32 Roflumilast in COPD
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The combined rate of moderate and severe AECOPD 
was reduced by 14% in the tiotropium study arm. The 
reduction in AECOPD was less than in the combina-
tion IHCS/LABA inhaler trials but the treatment arms 
in the combination inhaler trials were compared to 
placebo whereas in UPLIFT, tiotropium was added to 
regular treatment which often already included LABA, 
IHCS or combination IHCS/LABA therapy.31,32
An obvious question is whether combination of the 
three classes of inhaled medications, long-acting anti-
cholinergics (LAAC), IHCS, and LABA is superior 
to LAAC monotherapy, or to a combination of LABA 
and  LAAC.41  A  government  agency-funded  study 
incorporated an intent-to-treat analysis and a weighted 
Poisson regression model to account for all sources 
of variability to compare these treatment options in 
a double-blinded, randomized, three-arm trial.41 The 
combination of three classes of inhaled medications, 
LAAC, LABA, and IHCS, did not reduce AECOPD 
compared to tiotropium, the primary objective of the 
study, but triple combination therapy reduced severe 
AECOPD  requiring  hospitalization  and  improved 
both pulmonary function and quality of life scores.41 
Table 1. Design of the large COPD trials.
Trial (reference) Year reported Duration Primary objective Treatment arms
TRISTAN29 2003 1 year FEv1 pla, S, F, SFC
SZRAFRANSKI30 2003 1 year FEv1, severe exac pla, Bud, Form, Bud/Form
TORCH31 2007 3 years Mortality pla, S, F, SFC
OPTIMAL41 2007 1 year Exacerbation rate Tio, Tio + S, Tio + SFC
INSPIRE48 2008 2 years Exacerbation rate SFC, Tio
UPLIFT32 2008 4 years Rate of FEv1 decline pla, Tio
CLIMB33 2009 12 weeks FEv1 pla, Bud/Form
Abbreviations: pla, placebo; S, salmeterol; F, fluticasone; SFC, salmeterol fluticasone combination inhaler; Bud, budesonide; Form, formoterol; Bud/
Form, budesonide formoterol combination inhaler; Tio, tiotropium.
Table 2. Demographics of the large COPD trials.
Tristan Szrafranski TORCH OPTIMAL INSPIRE UPLIFT WELTE
(n = 1465) (n = 812) (n = 6184) (n = 449) (n = 1323) (n = 5993) (n = 660)
Mean age 63 64 65 68 65 65 62
% male 73 78 76 44 83 75 75
Smoking history 43 45 49 50 40 49 37
Current (%) 51 35 43 28 38 29 44
Pre FEv1 1.25 1.0 1.1 1.0 1.1 1.1 1.1
% predicted 44 36 44 39 39 39 38
Notes: Mean age is given in years. Smoking history is given in pack years. One pack year is the equivalent of smoking 20 cigarettes daily for one year. 
Current (%) proportion of patients that are current cigarette smokers. 
Abbreviations: n, number of patients randomized; % male, percentage of patients randomized that were males; Pre FEv1, FEv1 measured prior to 
treatment with bronchodilator expressed as l/s; % predicted, average FEv1 expressed as percent of the predicted value.
Subsequently, an industry-  sponsored study   compared 
the  addition  of  budesonide/formoterol  or    placebo 
to  tiotropium  treatment  and  showed  that  the 
  combination of the three types of inhaled medications 
reduced the number of AECOPD requiring treatment 
with systemic corticosteroids.33
There are several important caveats when consider-
ing these treatment trial findings. Most importantly, the 
majority of patients in these trials had GOLD stage III 
or GOLD stage IV disease, ie, a FEV1 less than 50% of 
predicted or less than 30% of predicted, respectively.1 
It  is  unclear  whether  the  results  are  applicable  to 
patients with milder disease. Anywhere from 25% to 
30% of the patients in the treatment arms and more 
than 40% in the placebo arms failed to complete the 
protocol in these studies.29–33,41 Since an intent-  to-treat 
analysis was usually employed, patients leaving the 
study  prematurely  were  often  treated  with  another 
regimen resulting in distortion of the results.42,48 Since 
more patients left the   placebo than the treatment arms 
and were subsequently treated with the medications 
that they were supposed to be compared to, the ben-
efits of therapy may have been underestimated.42Field
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The studies were designed to include a high risk 
group  at  baseline  so  that  the  intervention  could 
  demonstrate  a  benefit.  Most  patients  in  the  larger 
  treatment trials had GOLD stage III or stage IV   disease 
and at least one AECOPD in the year prior to   entering 
the  treatment  trial.  The  treatment  interventions 
  demonstrated clinically important benefits including 
a reduction in the number of moderate and severe 
AECOPD  but  patients  in  the  treatment  arms  still 
experienced an average of nearly one AECOPD per 
year.29–33,41,49  Considering  their  clinical  importance, 
the development of medications to further reduce the 
rate of AECOPD and their consequences is essential. 
A variety of different medication classes are currently 
undergoing study for treatment of COPD.7
Theophylline, a Nonselective 
Phosphodiesterase Inhibitor
Theophylline has been used since the 1930s for the 
treatment of asthma and COPD.50,51 It is a nonselective 
phosphodiesterase inhibitor with several potentially 
important  actions  including  bronchodilation, 
enhancement of skeletal muscle contractility, and it 
is a CNS stimulant.50,51 Phosphodiesterase hydrolyzes 
the  3´-phosphodiester  bond  in  cyclic  nucleotides 
terminating  their  activity.52 Theophylline  has  other 
effects including adenosine antagonism and histone 
deacetylase activity restoration.50 More recently, anti-
inflammatory effects have been recognized that may 
be important in COPD and asthma.51 Disadvantages 
include its narrow therapeutic window and potentially 
life-threatening and difficult-to-treat adverse effects 
including nausea and vomiting, cardiac arrhythmias, 
and  CNS  stimulation  and  seizures.  Theophylline 
overdoses  are  notoriously  difficult  to  manage  and 
severe  ones  may  require  charcoal  haemoperfusion 
dialysis.  It  is  metabolized  via  the  hepatic  P  450 
cytochrome enzyme pathways and drug interactions 
can affect serum levels of theophylline and a variety 
of other medications, either reducing their activity 
or  increasing  the  risk  of  toxicity.  Theophylline 
levels have to be measured periodically to insure a 
therapeutic effect and to avoid toxicity.
Selective PDE Inhibitors
Eleven families of PDE isozymes have been identified 
and their distribution varies in different types of cells.53,54 
Selective inhibitors of PDE5 relax vascular smooth 
muscle and have been very successfully   marketed as 
treatments for erectile dysfunction and more recently 
as treatment for pulmonary hypertension.55
PDE4 Inhibitors (PDE4i)
Adenylcyclase  catalyzes  the  conversion  of ATP  to 
cyclic adenosine 3′,5′-monophosphate (cAMP). Cyclic 
AMP is an important intracellular signal for a diverse 
array  of  neurotransmitters,  hormones,    cytokines 
and  medications  that  stimulate    membrane-bound 
adenyl cyclase.52 Phosphodiesterase (PDE) catalyzes 
the conversion of cAMP to its noncyclic monophos-
phateform, terminating its activity.  
Phosphodiesterase  4  (PDE4)  is  the  predominant 
isozyme in most immune and proinflammatory cells56 
(Table 3). It has an   absolute specificity for cAMP. Inhi-
bition of PDE4 activity increases intracellular concen-
trations of cAMP, down-regulating inflammatory cell 
activity.53 The PDE4 isozyme is also found in a variety 
of structural cells in the lung including bronchial epi-
thelial, endothelial, smooth muscle, and nerve cells.57
Cilomilast, was the first PDE4i to undergo exten-
sive  clinical  testing.58  Phase  3  clinical  trials  were 
underway when the decision was made to suspend its 
development because of an unfavourable side effect 
profile.59  Within  the  PDE4  isozyme  family,  there 
are differences between the forms seen in the cen-
tral nervous system (CNS) (PDE4D) and in immune 
Table  3.  Effects  of  roflumilast,  a  phosphodiesterase  4   
inhibitor, on various cell types.
Cell type Action of roflumilast
Macrophage TNF-α and LTC4 expression reduced
CD8+  
T lymphocyte
Cytokine production and lymphocyte 
proliferation reduced
Neutrophil IL-8 and LTB4 expression, 
phagocytosis and chemotaxis reduced
Eosinophil Degranulation, arachidonic acid,  
LTC4 and ROS reduced
Airway smooth  
muscle
Eotaxin expression reduced
Epithelial cell IL-6 and TNF-α production reduced
Endothelial cell vascular permeability and adhesion 
molecule expression reduced
Sensory nerve Neuropeptide secretion reduced
Fibroblast Eotaxin and ICAM-1 expression 
reduced
Abbreviations: TNFα, Tumor  necrosis  factor  alpha;  LT,  Leukotriene; 
IL,  interleukin;  ROS,  reactive  oxygen  species;  ICAM-1,  intercellular 
adhesion molecule-1.Roflumilast in COPD
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and  proinflammatory  cells  (PDE4B).59  Cilomilast 
  preferentially affects PDE4D causing an intolerable 
amount of nausea and vomiting.59
Roflumilast  has  proportionately  less  effect  on 
PDE4D  than  cilomilast  and  recently  was  the  first 
PDE4i approved for the treatment of COPD.60 It is a 
nonselective PDE4i and is less likely to cause nausea 
and emesis than cilomilast.61 It is also a more potent 
anti-inflammatory  than  cilomilast.61,62  Roflumilast 
reduces moderate and severe AECOPD in patients 
with COPD; particularly in those with more severe 
airway obstruction (FEV1 , 50% of predicted), the 
clinical phenotype of chronic bronchitis, and a his-
tory of AECOPD.63
Pharmacology of Roflumilast
The  pharmacokinetics  of  roflumilast  have  been 
studied in different populations including children, 
healthy adults, and both asthma and COPD patients.53 
Roflumilast  has  80%  oral  bioavailability  and  its 
absorption  is  not  affected  by  cigarette smoking  or 
food ingestion.53 Absorption is not affected by either 
magnesium  hydroxy-  or  aluminium  hydroxy-based 
antacids. Its main metabolite is roflumilast N-oxide 
which  also  potently  inhibits  the  PDE4B  isozyme. 
The times to peak concentration are 1.5 and 10 hours 
and elimination half lives are 10 and 20 hours, for 
  roflumilast and the N-oxide metabolite, respectively.64 
The N-oxide metabolite accounts for approximately 
90% of the PDE4B activity and provides reasonable 
PDE4i over 24 hours allowing for once daily oral 
administration.64
There are few clinically important drug interactions 
apart from potential concerns about the co-administration 
of  roflumilast  and  rifampin.65    Fluvoxamine  reduces 
clearance  of  roflumilast.53  Specifically,  there  are  no 
interactions with warfarin, erythromycin, ketoconazole, 
or midazolam. There are no significant interactions with 
a variety of respiratory medications including salbuta-
mol, formoterol or budesonide.53
Preclinical Data
Roflumilast inhibits mediator release from various immune 
and proinflammatory cells and from structural cells in 
the lung (Table 3).57 It reduces expression of CD11 on 
human leukocytes and reduces E-selectin expression in 
human endothelial cells.66 It also inhibits fibroblast and 
airway smooth muscle cell activity. Roflumilast reduced 
the severity of emphysema that developed in mice chron-
ically exposed to cigarette smoke.67 Neutrophil and mac-
rophage concentrations were reduced in the bronchial 
lavage fluid of cigarette exposed mice pretreated with 
roflumilast.68 In a comparative study in cigarette smoke-
exposed guinea pigs, roflumilast reduced the numbers of 
neutrophils, lymphocytes, and eosinophils, and reduced 
protein content in bronchoalveolar lavage fluid whereas 
treatment with corticosteroids only reduced the number 
of eosinophils.69
Roflumilast Studies in COPD Patients
Grootendorst and colleagues investigated the effects 
of roflumilast on induced sputum indices in patients 
with COPD.70 In a controlled, cross-over, placebo-
controlled study of four weeks duration, roflumilast-
improved both pre-and post-bronchodilator FEV1. The 
total number of inflammatory cells, and the   numbers 
of  neutrophils,  lymphocytes,  and  eosinophils  were 
reduced in the sputum during roflumilast   treatment.70 
Roflumilast  also  reduced  levels  of  inflammatory 
cell  markers  including  neutrophil  elastase,  IL-8, 
eosinophil cationic protein, and α-2 macroglobulin, a 
marker of increased microvascular permeability.70
A total of 516 COPD patients were randomized in 
a  parallel-design,  three-armed  study  comparing  26 
weeks treatment with Roflumilast 250 mcg daily and 
Roflumilast 500 mcg daily to placebo.71 Both doses of 
roflumilast improved FEV1 compared to the placebo 
arm. Morning peak flows and AECOPD rates were 
also improved with roflumilast.71
In a second three arm study, patients were either 
treated for 24 weeks with roflumilast 500 mcg daily, 
roflumilast 500 mcg daily for 12 weeks followed by 
placebo  for  12  weeks,  or  placebo  for  24  weeks.72 
In  patients  treated  with  roflumilast  for  24  weeks, 
FEV1 increased after one week and remained above 
  baseline for the duration of the study. In the patients 
treated  for  12  weeks,  FEV1  improved  during  the 
roflumilast   treatment period and then declined over 
the subsequent 12 weeks but remained better than 
pulmonary function in the placebo arm.72
Phase III Studies in COPD Patients
M2-107 or the RECORD study
The first large clinical trial with roflumilast was a three 
arm  parallel-design,  randomized,  placebo-controlled 
study that compared 500 mcg or 250 mcg given orally Field
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once  daily  to  treatment  with  placebo  for  24  weeks27 
(Table 4). A total of 1,413 patients were randomized. 
The mean post bronchodilator FEV1 was 54% of the 
predicted value, average smoking history was 42 pack-
years, and 46% of the subjects were still smoking at study 
entry (Table 5). Compared to treatment with placebo, 
both roflumilast 250 mcg and 500 mcg daily improved 
pre-and post bronchodilator FEV1, and SGRQ score, 
although  the  difference  did  not  reach  the  minimally 
clinically important difference of 4, and the number of 
AECOPD was reduced. More patients in the treatment 
groups failed to complete the protocol and they were 
more likely to experience diarrhea or nausea.27
M2-112 or the RATIO study
A subsequent study included patients with more severe 
COPD.73  The  mean  postbronchodilator  FEV1  was 
41% of predicted in the subjects who were random-
ized to treatment with daily oral roflumilast 500 mcg 
for 12 months or to placebo. Treatment with constant 
doses of IHCS, to a maximum of 2000 µg of beclom-
ethasone daily or its equivalent, and treatment with 
short-acting anticholinergics at constant doses were 
allowed but neither LABA nor LAAC were permitted. 
The co-primary objectives of the study were postbron-
chodilator FEV1 and the rate of moderate and severe 
AECOPD. Postbronchodilator FEV1 improved in the 
roflumilast-treated patients but the AECOPD rate did 
not. There were no differences in SGRQ between the 
two treatment groups. Patients treated with roflumilast 
were more likely to discontinue treatment and were 
more likely to experience nausea or diarrhea.73
M2-111 or the OPUS study
An  identical  study,  called  OPUS,  was  undertaken 
in another population but the results have not been 
published separately.74 However, a pooled analysis of 
Table 4. Reports of the large roflumilast trials.
Trial (ref) Year reported Duration Primary objective(s) Treatment arms
RECORD27 2005 24 weeks post FEv1, SGRQ R 500 µg OD, R 250 µg OD, placebo
RATIO73 2007 52 weeks post FEv1, exac* R 500 µg OD, placebo
OPUS74 2008 52 weeks post FEv1, exac* R 500 µg OD, placebo
AURA/HERMES63 2009 52 weeks pre FEv1, exac rate R 500 µg OD, placebo
EOS75 2009 24 weeks pre FEv1 R 500 µg OD, placebo
HELIOS75 2009 24 weeks pre FEv1 R 500 µg OD, placebo
Abbreviations: ref, reference number; SGRQ, St. George respiratory questionnaire score; post FEV1, postbronchodilator FEv1;  pre FEv1, prebronchodilator 
FEv1; exac, exacerbations; exac*, moderate and severe exacerbations; R, roflumilast; OD, daily.
these two identical studies, containing 2686 patients 
with a mean postbronchodilator FEV1 of 39% pre-
dicted, demonstrated a 13% reduction in the rate of 
AECOPD. Post hoc subgroup analyses demonstrated 
a more pronounced treatment effect in patients with 
the chronic bronchitis phenotype.74
M2-124 or the AURA study,  
M2-125 or the HERMES study
Based  on  the  pooled  analyses  of  the  data  from  the 
two previous studies, two identical placebo-controlled 
roflumilast studies were carried out in COPD patients 
with more severe disease, mean FEV1 less than 50% 
predicted, the clinical phenotype of chronic bronchitis, 
and a history of AECOPD.63 Patients were randomized 
to treatment with oral roflumilast 500 mcg daily for 
12 months or to placebo. The results of the two studies 
were pooled for analysis. Patients were allowed treat-
ment with LABA but neither IHCS nor LAAC were 
permissible. Patients were stratified according to their 
smoking history and whether they were LABA users. 
The co-primary study endpoints were prebronchodila-
tor FEV1 and the rate of moderate and severe AECOPD. 
A total of 3096 patients with a mean postbronchodila-
tor FEV1 of 36% of predicted were randomized. Both 
pre-  and  postbronchodilator  FEV1  improved  in  the 
roflumilast arm, 48 ml/s and 55 ml/s, respectively. The 
combined  moderate  and  severe AECOPD  rate  was 
17% less in the roflumilast-treated group.63
M2-127 or the EOS trial
Two  studies  of  the  effects  of  adding  roflumilast  to 
long-acting bronchodilators were reported in a separate 
publication.75 Patients in these studies had less severe 
airway  obstruction  than  in  the  M2-124  or  M2-125 
studies. The mean postbronchodilator FEV1 was 55% 
and 56% of predicted in the EOS and HELIOS studies, Roflumilast in COPD
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respectively.75 Chronic bronchitis was not a prerequisite 
for inclusion in the EOS study, but 79% of the patients 
recruited had chronic cough and sputum production. 
In the EOS study, patients taking salmeterol were ran-
domized to receive oralroflumilast 500 mcg daily for 
24 weeks or placebo. Both pre- and post-bronchodila-
tor FEV1 were greater in the roflumilast treated group, 
49 ml/s and 60 ml/s, respectively. There was a trend 
to  a  lower  rate  of AECOPD  among  the  roflumilast 
treated patients but the difference was not statistically 
significant. The median time to the first AECOPD and 
the proportion of patients with an AECOPD were less 
in the roflumilast treated patients.75
M2-128 or the HELIOS trial
In the HELIOS Study, patients treated with   tiotropium 
were randomized to treatment with oral roflumilast 
500 mcg daily for 24 weeks or to placebo.75 Chronic 
bronchitis  was  a  prerequisite  for  this  study.  The 
mean  FEV1  in  the  study  patients  was  56%  of  the 
  predicted value. In the roflumilast arm, pre- and post-
bronchodilator FEV1 improved 80 ml/s and 81 ml/s, 
respectively. There was trend to a lower AECOPD 
rate in the roflumilast arm but the difference was not 
statistically significant. The median time to the first 
AECOPD was greater and the proportion of subjects 
with an AECOPD was less in the roflumilast treated 
subjects. The EOS and HELIOS studies revealed that 
roflumilast improved pulmonary function in patients 
treated with long-acting bronchodilators.75
The effects of PDE4i in COPD were the   subject of 
a recent Cochrane Database review.76 Nine   controlled 
randomized  trials  with  roflumilast,    containing  data 
from 9211 patients, were included in the review. It 
concluded  that  roflumilast  improved  pulmonary 
function  in  patients  with  COPD  of  varying  sever-
ity and regardless of concurrent therapy. Small but 
statistically  significant  improvements  in  quality 
of life scores were reported in roflumilast patients 
but were not considered clinically important. Exer-
cise tolerance was not improved. Most importantly, 
roflumilast reduced AECOPD frequency (OR 0.78; 
95% CI 0.72–0.85). Weight loss occurred in roflumi-
last treated patients and they experienced more non-
serious  adverse  events,  particularly  gastrointestinal 
symptoms and headaches.76
Addition of Roflumilast to IHCS
That  patients  treated  with  long-acting  bronchodi-
lators benefited from the addition of roflumilast is 
not   surprising since the addition of anti-inflamma-
tory  IHCS  to  long-acting  bronchodilator  treatment 
improves  outcomes  in  patients  with  more  severe 
COPD.29–31,33  Roflumilast  is  also  anti-inflammatory 
but  has  a  different  anti-inflammatory  profile  than 
IHCS.  IHCS  have  a  greater  effect  on  eosinophils 
and CD4+ T lymphocytes whereas, in addition to its 
effects on these inflammatory cells, roflumilast is also 
effective against CD8+ T lymphocytes, neutrophils, 
and  CD68+  macrophages.57,59,70  Obvious  questions 
are whether roflumilast is beneficial in patients previ-
ously treated with IHCS and whether the addition of 
roflumilast to IHCS therapy, the combination of two 
anti-inflammatory medications, offers any benefits to 
Table 5. Demographics of the large roflumilast trials.
RECORD RATIO OpUs AURA/HERMES eOs HELIOS
(n = 1411) (n = 1513) (n = 1173) (n = 3091) (n = 933) (n = 743)
Mean age 64 65 64 64 65 64
% male 74 76 67 75 66 71
Smoking history 43 44 50 48 43 43
Current (%) 46 37 43 41 39 40
Pre FEv1 1.45 1.04 0.95 1.01 1.42 1.48
% predicted 51 37 32 33 52 53
Post FEv1 1.57 1.14 1.10 1.10 1.50 1.56
% predicted 55 41 36 36 55 56
Reprinted from Drug Design, Development and Therapy, Volume 4, Giembycz MA, Field SK, A 2010 update on roflumilast, a selective phophodiesterase 4 
inhibitor for the treatment of COPD, 147–158, Copyright (2010), with permission from Dove Medical Press Ltd.
Notes: Mean age is given in years. Smoking history is given in pack years. One pack year is the equivalent of smoking 20 cigarettes daily for one year. 
Current (%) proportion of patients that are current cigarette smokers. 
Abbreviations: n, number of patients randomized; % male, percentage of patients randomized that were males; Pre FEv1, FEv1 measured prior to 
treatment with bronchodilator expressed as l/s; % predicted, average FEv1 expressed as percent of the predicted value.Field
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COPD patients? In the AURA and Hermes studies, 
AECOPD  were  reduced  both  in  patients  with  and 
without a history of IHCS treatment.63
To investigate the effects of adding   roflumilast to 
IHCS, a post hoc analysis of two identical studies, 
RATIO  and  OPUS,  that  allowed  the  concomitant 
use of IHCS, up to the equivalent of 2000 mcg of 
beclomethasone/day, was undertaken. Approximately 
44% of the patients were being treated with IHCS 
and approximately 20% were receiving   combination 
IHCS  and  LABA  therapy.63,74  If  one  includes  the 
results of all patients in the two studies regardless 
of  their  IHCS  use,  roflumilast  reduced  moderate 
and severe AECOPD by 14.3% (P = 0.026). If the 
patients are stratified by IHCS use, treatment with 
roflumilast reduced moderate and severe AECOPD 
by  18.8%  (P  =  0.014)  and  7.7%  (P  =  0.55)  in 
patients with or without concomitant IHCS therapy, 
respectively.74
The  authors  hypothesized  that  concomitant 
IHCS  treatment  selected  for  COPD  patients  with 
more severe disease who were more likely to   suffer 
AECOPD.77  The  proportion  of  GOLD  stage  IV 
patients was greater in the IHCS treated cohort (28% 
versus  21%).  Consistent  with  this  hypothesis,  the 
IHCS-treated patients randomized to placebo had a 
higher AECOPD rate than non IHCS-treated patients 
randomized to placebo (0.89 versus 0.46) making the 
treatment effects easier to demonstrate.77
An Unexpected Benefit in Patients 
with Comorbid Diabetes Mellitus
An unexpected finding in patients with COPD and 
comorbid  diabetes  mellitus  (DM)  type  2  was  that 
roflumilast reduced fasting blood glucose and hemo-
globin A1c (HbA1c) levels.78 Presumably, this effect 
is mediated by the action of roflumilast on cAMP 
  levels since the small changes in weight would not be 
expected to have an effect of this magnitude.   Fasting 
blood glucose levels did not change in COPD patients 
without comorbid DM. These findings suggest that 
roflumilast may improve glycemic control in patients 
with co-morbid DM.78 In a separate study, roflumilast 
improved fructosamine levels, a marker of short-term 
DM control, and HbA1cin patients with treatment naive 
DM type 2 but who did not have COPD.79 Further 
studies will be required to determine how roflumilast 
affects DM control, whether DM outcomes improve, 
and whether it can prevent some of the complications 
of DM.
Safety Data
Roflumilast  treated  patients  were  more  likely  to 
  discontinue  therapy.27,63,73,75  Serious  adverse  events 
were  similar  in  roflumilast-  and  placebo-treated 
patients in a pooled analysis of 12,054 subjects in 
14  roflumilast  treatment  trials.80  Diarrhea  (10.1% 
vs. 2.6%), nausea (5.2% vs. 1.4%), and headaches 
(4.6% vs. 2.0%) were more common than in place-
bo-treated  patients.80  Vomiting  occurred  much  less 
frequently.63  These  symptoms  generally  occurred 
early in the treatment period.27 Roflumilast patients 
lost an average of 2.2 kg compared to the placebo-
treated  patients.  Weight  loss  was  primarily  due  to 
loss of fat mass and was greater in obese and less 
in underweight patients.80 The weight loss was par-
tially reversible within 12 weeks of treatment ces-
sation.81  Cardiovascular  adverse  events  (5.7%  vs. 
5.9%)  and  serious  cardiovascular  adverse  events 
(1.8% vs. 2.1%) were slightly less common in the 
roflumilast  treated  patients  than  in  the  placebo 
groups.80 Mortality and serious adverse events were 
not  increased  in  roflumilast  treated  patients.  Pneu-
monia rates were not increased in roflumilast treated 
patients compared to placebo treated patients. Neurop-
sychiatric adverse events and rates of the development 
of some solid tumours were infrequent but occurred 
more commonly in roflumilast treated patients.81
Summary
Treatment with tiotropium, LABA, IHCS, or combi-
nation IHCS-LABA inhalers may reduce AECOPD 
but does not eliminate them29,30,31,33 (Table 6). Patients 
who experience frequent AECOPD have worse qual-
ity of life scores, experience more rapid declines in 
pulmonary  function,  and  have  a  greater  mortality 
rate. Roflumilast reduced AECOPD in patients treated 
with short-acting bronchodilators, IHCS, LABA or 
LAAC.63,74,75 In a pooled analysis of 7 studies which 
included 7457 patients, the odds ratio of an AECOPD 
in subjects treated with roflumilast 500 µg daily was 
0.77 (OR 95% CI 0.69–0.87).75
The benefits of roflumilast were greatest in patients 
with  more  severe  COPD,  GOLD  stage  III  and  IV 
disease,  and  with  the  chronic  bronchitis    clinical 
phenotype, and a history of AECOPD. Its effects on Roflumilast in COPD
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symptoms  and  consequently  on  quality  of  life  are 
  relatively  small  since  it  is  an  anti-inflammatory.82 
Although  roflumilast  is  not  a  bronchodilator,  it 
improved   pulmonary function when combined with 
both short- and long-acting bronchodilators.63,75 The 
magnitude of the FEV1 increase was similar to that 
reported in other large COPD treatment trials with 
bronchodilators and with combination IHCS-LABA 
inhalers.29–33,41 The most common adverse effects were 
gastrointestinal symptoms and headaches. Weight loss 
averaged 2.2 kg more than in the placebo group but was 
primarily due to fat loss. Roflumilast improved pul-
monary function and reduced AECOPD but not respi-
ratory symptoms or quality of life.76 Since roflumilast 
is not a bronchodilator, the lack of symptom improve-
ment is not unexpected.82 Roflumilast was effective 
whether given alone or in combination with long act-
ing bronchodilators.29,30,31,33 Patients treated with IHCS 
also appear to benefit from roflumilast therapy. In the 
roflumilast clinical trials, there were more dropouts in 
the roflumilast arms than in patients treated with pla-
cebo. Convincing patients to continue treatment with 
roflumilast may be a challenge.76 The lack of a benefi-
cial effect on respiratory symptoms and the adverse 
effect profile may interfere with compliance.
Clinical Positioning
The majority of patients in the roflumilast clinical stud-
ies had severe (GOLD stage III) or very severe (GOLD 
stage IV) COPD. The benefits of the   medication were 
less  obvious  in  the  earlier  studies  which  included 
patients  with  milder  disease.  Although  roflumilast 
improved pulmonary function and reduced AECOPD, 
it only mildly improved symptoms and quality of life 
scores. Patients with milder disease generally do not 
experience  frequent  AECOPD.  Consequently,  any 
benefit was not as impressive as in the studies with 
patients with more severe disease. There is not enough 
evidence to recommend its use in patients with mild 
disease so it will not have an indication as a first-line 
treatment. The data for its use was most compelling in 
patients with the chronic bronchitis phenotype and a 
history of frequent AECOPD.83 Patients with chronic 
bronchitis have more severe airway inflammation that 
increases further with exacerbations which may explain 
why  these  features  were  predictive  of  a  beneficial 
response to an anti-inflammatory medication. Exacer-
bations were decreased and lung function improved 
when patients with that clinical profile were treated 
with roflumilast. It was effective when added to short-
acting bronchodilators, long-acting beta agonists, or 
to tiotropium.63,75 A post hoc analysis of two earlier 
studies demonstrated that it was also effective when 
added to IHCS.74 Although contraindicated as mono-
therapy in COPD, IHCS appear to be beneficial when 
combined with LABAs in patients with more severe 
disease.29–31 There are no head-to-head studies com-
paring the effectiveness of roflumilast versus IHCS 
as add-on therapy to long-acting bronchodilators but 
the addition of roflumilast to LABA resulted in simi-
lar reductions in the exacerbation rate as the addition 
of IHCS.29–31,75 Another option would be the addition 
Table 6. Impact of various treatment interventions on AECOPD frequency.
TRIAL Publication year Intervention Reduction in annual exacerbation   
rate treatment vs. placebo
TRISTAN 2003 SFC vs. Pla 0.97 vs. 1.30 (all)
Szrafranski* 2003 Bud-Form vs. Pla 1.42 vs. 1.87 (all)
TORCH 2007 SFC vs. Pla 0.85 vs. 1.13
UPLIFT 2008 Tio vs. Pla 0.73 vs. 0.85
OPTIMAL 2007 SFC/Tio vs. Tio (all) 1.37 vs. 1.61
CLIMB 2009 Bud-Form/Tio vs. Tio 0.124 vs. 0.326 (3 months)
RECORD 2005 R vs. Pla 0.75 vs. 1.13 (500 µg) (all)
RATIO 2007 R vs. Pla 0.86 vs. 0.92 (P = ns)
including OPUS 2011 R vs. Pla 0.56 vs. 0.64
AURA/HERMES 2009 R vs. Pla 1.14 vs. 1.37
EOS 2009 R/S vs. S 2.4 vs. 1.9 (all) (P = ns)
HELIOS 2009 R/Tio vs. Tio 2.2 vs. 1.8 (all) (P = ns)
Abbreviations: all, all exacerbations were compared; Bud form, budesonide formoterol combination inhaler; Pla, placebo; R, roflumilast; S, salmeterol; 
SFC, salmeterol fluticasone combination inhaler; Tio, tiotropium; ‘including OPUS’, combination of the data from two identically designed studies, the 
RATIO and OPUS studies; *, name of first author; ns, not statistically significant.Field
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of roflumilast to combined LABA and LAAC therapy. 
The addition of IHCS to the combination of LABA 
and LAAC did not reduce the overall AECOPD rate 
but did reduce the rate of severe AECOPD requiring 
hospitalization.41 The increase in pulmonary function 
reported with the addition of IHCS to LABA was simi-
lar to the increases demonstrated by adding roflumilast 
to either class of long-acting bronchodilator.75 A clini-
cal trial comparing the addition of IHCS versus the 
addition of roflumilast to combined LAAC and LABA 
therapy could determine which strategy is superior.
Based on expert opinion, the addition of theophyl-
line is recommended if patients remain symptomatic 
despite treatment with a combination of inhaled long-
acting  bronchodilators  and  IHCS.4  Theophylline 
has  both  bronchodilator  and  anti-inflammatory 
properties.50,51  Although  there  are  no  comparative 
studies, this would also seem like a reasonable place 
to position roflumilast in the treatment algorithm. A 
clinical trial comparing the addition of theophylline 
or roflumilast to the combination of LAAC, LABA, 
and  IHCS  could  resolve  which  strategy  is  more 
effective.
An obvious question with any new medication is 
whether it will be popular with clinicians and patients 
and whether it will be successful in the marketplace.76 
Initially, its use will be limited to patients with more 
severe disease since benefits were minimal in patients 
with milder disease and unlike the large trials that 
investigated the effects of long-acting bronchodilators 
and  combination  IHCS-LABA  inhalers,  more  trial 
patients dropped out of the roflumilast treatment arms 
than the placebo arms. These medications improved 
respiratory  symptoms  and  had  greater  effects  on 
  quality of life scores than reported with roflumilast.29–33 
It appears that treatment with roflumilast will reduce 
the cost of care for patients with more severe COPD 
which  should  convince  governments  and  3rd  party 
payers to cover the costs of this novel medication.84 
Roflumilast reduced AECOPD and improved pulmo-
nary function in patients with more severe disease but 
it had a minimal effect on symptoms and quality of 
life and gastrointestinal and headache adverse events 
were more common in the treatment arms.76 It will 
be important to see whether patients will be willing 
to remain on chronic therapy with a medication that 
does not necessarily make them feel better.76 This will 
likely determine its success in the clinical setting.
Abbreviations
AECOPD,  acute  exacerbation  of  COPD;  95%  CI, 
95% confidence interval; COPD, chronic obstructive 
pulmonary disease; CXCL, chemokine CXC ligand; 
DM,  diabetes  mellitus;  ECLIPSE,  ‘Evaluation  of 
COPD   Longitudinally to Identify Predictive   Surrogate 
  End-points’ study; GOLD, Global initiative for chronic 
Obstructive Lung Disease; HbA1c, hemoglobin A1c; 
IHCS, inhaled corticosteroid; IL, interleukin; LAAC, 
long acting anti-cholinergic; LABA, long-acting beta 
agonist; OR, odds ratio; PDE4, phosphodiesterase 4; 
PDE4i,  phosphodiesterase  4  inhibitor;  SGRQ,  St. 
George respiratory questionnaire; TORCH, TOwards 
a Revolution in COPD Health trial; TNF-α, tumour 
necrosis factor-α.
Disclosures
Author(s) have provided signed confirmations to the 
  publisher  of  their  compliance  with  all  applicable 
legal and ethical obligations in respect to declaration 
of    conflicts  of  interest,  funding,  authorship  and 
contributorship,  and  compliance  with  ethical 
requirements in respect to treatment of human and 
animal test subjects. If this article contains identifiable 
human subject(s) author(s) were required to supply 
signed patient consent prior to publication. Author(s) 
have confirmed that the published article is unique and 
not under consideration nor published by any other 
publication and that they have consent to reproduce 
any copyrighted material. The peer reviewers declared 
no conflicts of interest.
References
1.  Global  Initiative  for  Chronic  Obstructive  Lung  Disease.  Global  strategy 
for  diagnosis,  management,  and  prevention  of  COPD.  http://www.nhlbi.
goldcopd.org.
2.  Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for 
COPD globally? Chest. 2010;138:3–6.
3.  Hogg JC, Chu F, Utokaparach S, et al. The nature of small-airway obstruction 
in chronic obstructive pulmonary disease. New Engl J Med. 2004;350(26): 
2645–53.
4.  O’Donnell  DE, Aaron  S,  Bourbeau  J,  et  al.  Canadian  Thoracic  Society 
  recommendations for management of chronic obstructive pulmonary disease-
2007 update. Can Respir J. 2007;14(Suppl B):B5–B32.
5.  Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in   peripheral 
airways of smokers with chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med. 1998;157:822–6.
6.  Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic 
obstructive  pulmonary  disease  and  systemic  inflammation:  a  systematic 
review and a meta-analysis. Thorax. 2004;59:574–80.
7.  Barnes PJ. The cytokine network in COPD. Am J Respir Cell Mol Biol. 2009; 
41(6):631–8.
8.  Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally 
to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008; 
31:869–73.Roflumilast in COPD
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2011:5  69
  9.  Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. 
Eur Respir J. 2009;33:1165–85.
  10.  Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause 
and prevention. Lancet. 2007;370:786–96.
  11.  Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA.   Relationship 
between  exacerbation  frequency  and  lung  function  decline  in  chronic 
obstructive pulmonary disease. Thorax. 2002;57:847–52.
  12.  Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. 
Effect of exacerbation on quality of life in patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22.
  13.  Chapman KR, Bhutani M, Bourbeau J, et al. The hospital burden of COPD 
in Canada. Am J Respir Crit Care Med. 2010;181:A1500.
  14.  Hoogendoorn  M,  Hoogenveen  RT,  Rutten-van  Molken  MP,  Vestbo  J, 
  Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and 
  statistical modeling approach. Eur Respir J. 2011;37:508–15.
  15.  Connors AF,  Dawson  NV, Thomas  C,  et  al.  Outcomes  following  acute 
  exacerbation of severe chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med. 1996;154:959–67.
  16.  Nie JX, Wang L, Upshur REG. Mortality of elderly patients in Ontario after 
admission for chronic obstructive pulmonary disease. Can Respir J. 2007; 
14:485–9.
  17.  Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in 
chronic  obstructive  pulmonary  disease.  New  Engl  J  Med.  2010;363: 
1128–38.
  18.  Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production 
are associated with frequent exacerbations and hospitalizations in COPD 
subjects. Chest. 2009;135:975–82.
  19.  Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with 
increased  risk  of  exacerbation  and  hospital  admission  in  a  cohort  of 
  ambulatory  COPD  patients:  a  multiple  logistic  regression  analysis. The 
EOLO Study Group. Respiration. 2000;67:495–501.
  20.  Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations 
and hospitalizations due to COPD. Chest. 2007;131:20–28.
  21.  Anzueto A,  Sethi  S,  Martinez  FJ.  Exacerbations  of  chronic  obstructive 
  pulmonary disease. Proc Am Thorac Soc. 2007;4:554–64.
  22.  Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and 
exacerbations of chronic obstructive pulmonary disease. New Engl J Med. 
2002;347:465–7.
  23.  Sethi S, Wrona C, Grant BJB, Murphy TF. Strain-specific immune response 
to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med. 2004;169:448–53.
  24.  Tager I, Speizer FE. Role of infection in chronic bronchitis. New Engl J 
Med. 1975;292:563–71.
  25.  Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GKM, 
Nelson  NA. Antibiotic  therapy  in  exacerbations  of  chronic  obstructive 
  pulmonary disease. Ann Intern Med. 1987;106:196–204.
  26.  Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after 
emergency treatment of chronic obstructive pulmonary disease. New Engl J 
Med. 2003;348:2618–25.
  27.  Rabe  KF,  Bateman  ED,  O’Donnell  DE,  Witte  S,  Bredenbroker  D, 
Bethke TD. Roflumilast-an oral anti-inflammatory treatment for chronic 
obstructive    pulmonary  disease:  a  randomized  controlled  trial.  Lancet. 
2005;366(5):63–71.
  28.  Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for 
the prevention of exacerbations of COPD. New Engl J Med. 2011;364: 
1093–1103.
  29.  Calverley  PM,  Pauwels  R,  Vestbo  J,  et  al.  Combined  salmeterol  and 
fluticasone  in  the  treatment  of  chronic  obstructive  pulmonary  disease:   
a   randomized controlled trial. Lancet. 2003;361:449–56.
  30.  Szrafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/
formoterol in the management of chronic obstructive pulmonary disease. 
Eur Respir J. 2003;21:74–81.
  31.  Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone 
propionate and survival in chronic obstructive pulmonary disease. New Engl 
J Med. 2007;356:775–89.
  32.  Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic 
obstructive pulmonary disease. New Engl J Med. 2008;359:1543–54.
  33.  Welte  T,  Miravitlles  M,  Hernandez  P,  et  al.  Efficacy  and  tolerability 
of    budesonide/formoterol  added  to  tiotropium  in  patients  with  chronic 
  obstructive  pulmonary  disease.  Am  J  Respir  Crit  Care  Med.  2009;180: 
741–50.
  34.  Vestbo J, Srensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect 
of inhaled budesonide in mild and moderate chronic obstructive pulmonary 
disease: a randomised controlled trial. Lancet. 1999;353:1819–23.
  35.  Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with 
inhaled budesonide in persons with mild chronic obstructive pulmonary 
  disease who continue smoking. European Respiratory Society Study on 
Chronic  Obstructive  Pulmonary  Disease.  New  Engl  J  Med.  1999;340: 
1948–53.
  36.  Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. 
  Multicentre  randomised,  placebo-controlled  trial  of  inhaled  fluticasone 
propionate in patients with chronic obstructive pulmonary disease. Lancet. 
1998;351:773–80.
  37.  Burge P, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. 
  Randomised, double blind, placebo controlled study of fluticasone proprionate 
in patients with moderate to severe chronic obstructive pulmonary disease: 
the ISOLDE trial. BMJ. 2000;320:1297–303.
  38.  Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in 
chronic obstructive pulmonary disease. Thorax. 2005;60;992–7.
  39.  Suissa  S,  Ernst  P,  Vandemheen,  Aaron  SD.  Methodological  issues  in 
therapeutic trials in COPD. Eur Respir J. 2008;31:927–33.
  40.  Wouters EFM, Postma DS, Fokkens B, et al. Withdrawal of fluticasone 
propionate from combined salmeterol/fluticasone treatment in patients with 
COPD causes immediate and sustained disease deterioration: a randomized 
controlled trial. Thorax. 2005;60:480–7.
  41.  Aaron SD, Vandenheem KL, Fergusson D, et al. Tiotropium in combination 
with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic 
obstructive pulmonary disease. Ann Intern Med. 2007;146:545–55.
  42.  Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and read-
mission in elderly patients with chronic obstructive pulmonary disease. Am 
J Respir Crit Care Med. 2001;164:580–4.
  43.  Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive 
  pulmonary  disease.  Immortal  time  bias  in  observational  studies.  Am  J 
Respir Crit Care Med. 2003;168:49–53.
  44.  Suissa  S.  Statistical  treatment  of  exacerbations  in  therapeutic  trials  of 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 
173:842–6.
  45.  Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted 
immortal time. Eur Respir J. 2004;23:391–5.
  46.  Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in 
chronic obstructive pulmonary disease and the risk for hospitalization for 
pneumonia. Am J Respir Crit Care Med. 2007;176:162–6.
  47.  Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk 
of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care 
Med. 2011;183:675–8.
  48.  Calverley PMA, Rennard SI. What have we learned from large treatment 
trials in COPD? Lancet. 2007;370:774–85.
  49.  Wedzicha  JA,  Calverley  PMA,  Seemungal  TA,  Hagan  G,  Ansari  Z, 
Stockley  RA. The  prevention  of  chronic  obstructive  pulmonary  disease 
exacerbations by salmeterol/fluticasone propionate ortiotropium bromide. 
Am J Respir Crit Care Med. 2008;177:19–26.
  50.  Barnes PJ. Theophylline. New perspectives for an old drug. Am J Respir 
Crit Care Med. 2003;167:813–8.
  51.  Barnes PJ. Theophylline for COPD. Thorax. 2006;61:742–3.
  52.  Bender AT,  Beavo  JA.  Cyclic  nucleotide  phosphodiesterases:  molecular 
regulation to clinical use. Pharmacol Rev. 2006;58:488–520.
  53.  Giembycz  MA,  Field  SK.  Roflumilast:  first  phosphodiesterase  inhibitor 
approved for treatment of COPD. Drug, Design, Development and Therapy. 
2010;4:147–158.
  54.  Torphy  TJ.  Phosphodiesterase  isozymes:  molecular  targets  for  novel 
  antiasthma agents. Am J Respir Crit Care Med. 1998;157:351–70.
  55.  Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors 
approved for the treatment of erectile dysfunction. Circulation. 2004;110: 
3149–55.Publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Field
70  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2011:5
  56.  Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory 
effects  of  cyclic  AMP  phosphodiesterase  (PDE)  type  4  inhibitors. 
Immunopharmacology. 2000;47:127–62.
  57.  Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory 
lung disease. Drugs. 2003;63:2575–94.
  58.  Rennard SI, Schacter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: 
results  of  the  6-month,  placebo  controlled  study  of  a  potent,  selective 
inhibitor of phosphodiesterase 4. Chest. 2006;129:55–66.
  59.  Lipworth  BJ.  Phosphodiesterase-4  inhibitors  for  asthma  and  chronic 
obstructive pulmonary disease. Lancet. 2005;365:167–75.
  60.  European  Medicines  Agency.  DAXAS.  Roflumilast.  www.ema.europa.
eu/docs/en_GB/document_library/EPA_summary_for_the_public/human/ 
001179/WC500095211.pdf.
  61.  Field SK. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the 
management of COPD and asthma. Expert Opin Investig Drugs. 2008;17: 
811–8.
  62.  Hatzelmann  A,  Schudt  C.  Anti-inflammatory  and  immunomodulatory 
potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp 
Ther. 2001;297:267–79.
  63.  Calverley  PMA,  Rabe  KF,  Goehring  U-M,  Kristiansen  S,  Fabbri  LM, 
  Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary 
disease: two randomized clinical trials. Lancet. 2009;374:684–95.
  64.  David M, Zech K, Seiberling M, Weimar C, Bethke TD. Roflumilast, a 
novel, oral, selective PDE4 inhibitor, shows high absolute bioavailability.   
J Allergy Clin Immunol. 2004;113:S220–S221.
  65.  Nassr N, Hunnemeyer A, Herzog R, et al. Effects of rifampicin on the 
  pharmacokinetics of roflumilast and roflumilast N-oxide inhealthy subjects. 
Br J Clin Pharmacol. 2009;68:580–7.
  66.  Sanz M-J, Cortijo J, Taha MA, et al. Roflumilast inhibits   leukocyte-endothelial 
cell  interactions,  expression  of  adhesion  molecules  and  microvascular 
  permeability. Br J Pharmacol. 2007;152:481–92.
  67.  Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast 
fully prevents emphysema in mice chronically exposed to cigarette smoke. 
Am J Respir Crit Care Med. 2005;172:848–53.
  68.  Martorana PA, Lunghi B, Lucattelli M, De Cunto G, Beume R, Lungarella G. 
Effect of roflumilast on inflammatory cells in the lungs of cigarette-exposed 
mice. BMC Pulm Med. 2008;8:17.
  69.  Fitz Gerald MF, Spicer D, McAulay AE, Wollin L, Beume R. Roflumilast 
but not methylprednisolone inhibited cigarette-smoke-induced pulmonary 
inflammation in guinea pigs. Eur Respir J. 2006;28(Suppl 50):663S.
  70.  Grootendorst DC, Gauw SA, Verhoosel RM, et al. The PDE4 inhibitor 
roflumilast reduces sputum neutrophil and eosinophil numbers in patients 
with COPD. Thorax. 2007;62:1081–7.
  71.  Bredenbroker D, Syed J, Leichtl S, Rathgeb F, Wurst W. Roflumilast, a 
new orally active, selective phosphodiesterase 4 inhibitor, is effective in 
the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2002; 
20 (Suppl 38)374S.
  72.  Boszormenyi-Nagy G, Pieters WR, Steffen H, et al. The effect of roflumilast 
treatment and subsequent withdrawal in patients with COPD. Am J Respir 
Crit Care Med. 2005;169:A544.
  73.  Calverley PMA, Sanchez-Toril F, McIvor RA, Teichmann P, Bredenbroeker D, 
Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med. 2007;176:154–61.
  74.  Rennard SI, Calverley PMA, Goehring UM, Bredenbroker D,   Martinez FJ. 
Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance 
of defining different subsets of patients with COPD. Respiratory Research 
2011,12:18. http://respiratory-research.com/12/1/18.
  75.  Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in 
moderate-to-severe  chronic  obstructive  pulmonary  disease  treated  with 
  longacting bronchodilators: two randomized clinical trials. Lancet. 2009; 
374:695–703.
  76.  Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011 
May 11;5:CD002309. The Cochrane Collaboration 2011, Issue 5. http://
www.the cochranelibrary.com.
  77.  Calverley PMA, Martinez F, Goehring U, et al. Defining patient populations 
in COPD: experience with roflumilast. COPD 7, June 30-July 2, 2010, 
  Birmingham, UK. A48;abstract.
  78.  Wouters E, Teichmann P, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast 
on glucose levels in patients with COPD and diabetes mellitus type 2.   Eur 
Respir  J  2010:P4002.  http://www.ersnet.org/learning_resources_player/
abstract_print_10/main_frameset.htm.
  79.  Wouters EFM, Teichmann P, Brose M, Goke B, Rabe KF, Fabbri LM. Effects 
of roflumilast, a phosphodiesterase 4 inhibitor, on glucose   homeostasis in 
patients with treatment-naive diabetes (type 2). Am J Respir Crit Care Med. 
2010;181:A4471.
  80.  Calverley PMA, Fabbri LM, Rabe KF, Mosberg H. Roflumilast in the treatment 
of COPD: a pooled safety analysis. Eur Respir J. 2010: abstract P4001. http://
www.ersnet.org/learning_resources_player/abstract_print_10/main_frameset.
htm.
  81.  Martinez FJ, Rabe KF, Wouters EFM, et al. Time course and reversibility 
of weight decrease with roflumilast, a phosphodiesterase 4 inhibitor. Am J 
Respir Crit Care Med. 2010;181:A4441.
  82.  Wollin  L,  Bundschuh  DS,  Wohlsen  A,  et  al.  Inhibition  of  airway 
hyperresponsiveness and pulmonary inflammation by roflumilast and other 
PDE4 inhibitors. Pulm Pharmacol Ther. 2006;19:343–52.
  83.  Bateman ED, Calverley PMA, Fabbri LM, et al. Efficacy of roflumilast in 
patients with a history of frequent exacerbations: pooled data from pivotal 
12-month studies. Eur Respir J. 2010: abstract P4003 http://www.ersnet.
org/learning_resources_player/abstract_print_10/main_frameset.htm.
  84.  Rutten-van  Molken  MPMH,  van  Nooten  FE,  Lindemann  M, 
Caeser M, Calverley PMA. A 1-year prospective cost-effectiveness analysis 
of   roflumilast for the treatment of patients with severe chronic obstructive 
pulmonary disease. Pharmacoeconomics. 2007;25:695–711.